Navigation Links
Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014
Date:8/5/2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lower Limb Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lower Limb Muscle Spasticity 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials by E7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20

Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lower Limb Muscle Spasticity Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
Merz Pharma GmbH & Co. KgaA 28
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 28
Ipsen S.A. 29
Clinical Trial Overview of Ipsen S.A. 29
Allergan, Inc. 30
Clinical Trial Overview of Allergan, Inc. 30
GlaxoSmithKline plc 31
Clinical Trial Overview of GlaxoSmithKline plc 31
Clinical Trial Overview of Top Institutes / Government 32
The University of Tokushima 32
Clinical Trial Overview of The University of Tokushima 32

Tehran University of Medical Sciences 33
Clinical Trial Overview of Tehran University of Medical Sciences 33
Danish Pain Research Center 34
Clinical Trial Overview of Danish Pain Research Center 34
Assistance Publique Hopitaux De Marseille 35
Clinical Trial Overview of Assistance Publique Hopitaux De Marseille 35
Five Key Clinical Profiles 36
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 114

List of Tables

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12

Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23

Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 28
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 29
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 30
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 31
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Tokushima, 2014* 32
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 33
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Pain Research Center, 2014* 34
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique Hopitaux De Marseille, 2014* 35

List of Figures

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 12
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17

Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 113

To order this report: Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Breakthrough Novation Applications Empower Childrens Hospital Association Members to Lower Costs, Increase Quality
2. Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40.
3. Physicians Are Urged to Call the Corporate Whistleblower Center with Proof of Physician Pay Offs from Pharmaceutical Companies
4. Corporate Whistleblower Center Advises Medical Doctors and Pharmaceutical Marketing Reps Who Have Proof of Drug Companies Selling Off-Label Drugs in Any State to Call About Federal Whistleblower Reward Programs
5. New Study: Medicare Preferred Pharmacy Network Plans Offer Lower Average Premiums, Same Quality as Non-Preferred Network Plans
6. Florida Attorney Gary M. Farmer, Jr. Settles Third Whistleblower Drug Case for $1.27 Billion
7. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
8. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
9. The Gary and Mary West Foundation and West Health Institute create new Center for Medical Interoperability to improve patient safety and lower costs of health care
10. Flower Orthopedics Introduces New Standards for Delivering Cost-effective Orthopedic Surgery
11. Grant & Eisenhofer Represents Whistleblowers in Justice Dept. $257 Million Civil Settlement with Wyeth over Unlawful Marketing of Rapamune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016   Bernstein Liebhard LLP today ... the United States District Court for the District of ... "Class") consisting of all persons or entities who purchased common ... INSY ) from March 3, 2015 through January 25, ... of its officers with violations of the Securities Exchange Act ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
Breaking Medicine News(10 mins):